Navigating 7 Analyst Ratings For Chemours
Portfolio Pulse from Benzinga Insights
In the past three months, 7 analysts have shared their ratings on Chemours (NYSE:CC), with a mix of bullish and bearish sentiments. The average 12-month price target has decreased by 13.58%, indicating a negative shift in sentiment. Analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Chemours faces challenges with a revenue decline of -6.39% over three months, but maintains strong financial health with a high net margin, ROE, and ROA.
September 25, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chemours has seen a negative shift in analyst sentiment with a 13.58% decrease in the average price target. Despite revenue challenges, the company maintains strong financial health indicators like net margin, ROE, and ROA.
The decrease in the average price target by 13.58% and the lowering of ratings by several analysts indicate a negative sentiment towards Chemours in the short term. This is compounded by a revenue decline of -6.39%. However, the company's strong financial health metrics like net margin, ROE, and ROA provide some stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100